The burden of congenital hyperinsulinism in the United Kingdom: a cost of illness study

Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient

(2017) Indraneel Banerjee et al.   Orphanet Journal of Rare Diseases

mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic Success

(2016) Marie Szymanowski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Diagnosis and Management of Hyperinsulinaemic Hypoglycaemia

(2015) Klára Roženková et al.   Journal of Clinical Research in Pediatric Endocrinology

Long-Term Follow-Up of Children With Congenital Hyperinsulinism on Octreotide Therapy

(2014) Huseyin Demirbilek et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sirolimus Therapy in Infants with Severe Hyperinsulinemic Hypoglycemia

(2014) Senthil Senniappan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK

(2014) M. Evans et al.   JOURNAL OF MEDICAL ECONOMICS

Sustainable rare diseases business and drug access: no time for misconceptions

(2013) Pierrick Rollet et al.   Orphanet Journal of Rare Diseases

Glucose Metabolism in 105 Children and Adolescents After Pancreatectomy for Congenital Hyperinsulinism

(2011) J. Beltrand et al.   DIABETES CARE

Congenital hyperinsulinism: current trends in diagnosis and therapy

(2011) Jean-Baptiste Arnoux et al.   Orphanet Journal of Rare Diseases